FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023002011> ?p ?o ?g. }

• W3023002011 endingPage "e204339" @default.
• W3023002011 startingPage "e204339" @default.
• W3023002011 abstract "Using corticosteroids to treat acute demyelinating optic neuritis has been identified as an area for shared decision-making. However, no analysis exists to support personalized shared decision-making that considers long- and short-term treatment benefits.To develop models of individual-level visual outcomes for patients with optic neuritis.This secondary analysis of the Optic Neuritis Treatment Trial (ONTT), a randomized clinical trial, was performed at 14 academic eye centers and 1 large community eye center. Adults aged 18 to 46 years with incident acute unilateral optic neuritis within 8 days of vision loss onset were included. Data were collected from July 1988 to June 1991, downloaded on October 15, 2018, and analyzed from January 24, 2019, to February 20, 2020, using multivariable linear regression modeling.Intravenous corticosteroids vs placebo.Visual acuity (VA) at 1 year. Secondary outcomes were 1-year contrast sensitivity (CS) and VA and CS at 15 and 30 days. Independent variables included age, sex, race, multiple sclerosis status, optic neuritis episodes in the fellow eye, vision symptoms (days), pain, optic disc swelling, viral illness, treatment group, and baseline VA or CS.Of the 455 participants, median age was 31.8 (interquartile range [IQR], 26.3-37.0) years; 350 (76.9%) were women; and 388 (85.3%) were white. For 410 participants (90.1%) with 1-year outcomes, median VA improved from 20/66 (IQR, 20/28-20/630) at enrollment to 20/17 (IQR, 20/14-20/21) at 1 year. Baseline VA was the primary variable associated with 1-year VA (regression coefficient, 0.056 [95% CI, 0.008-0.103]; P = .02) if baseline VA was better than count fingers (CF). At 15 days, baseline VA and treatment status were associated with VA in those participants with baseline VA better than CF (regression coefficient, 0.305 [95% CI, 0.231-0.380]; F = 9.42; P < .001). However, the difference of medians (20/18 [95% CI, 20/17-20/19] with intravenous corticosteroids vs 20/23 [95% CI, 20/21-20/26] with placebo) was small for the median VA (20/66) in the trial. Treatment was not associated with 15-day or 1-year VA in participants with baseline VA of CF or worse.In this study, long-term VA was associated with severity of baseline vision loss. Early benefits with intravenous corticosteroid treatment were limited to participants with baseline VA better than CF. However, the early, temporary benefit of intravenous corticosteroids is of questionable clinical significance and should be weighed against potential harms." @default.
• W3023002011 created "2020-05-13" @default.
• W3023002011 creator A5007895609 @default.
• W3023002011 creator A5009520384 @default.
• W3023002011 creator A5014104761 @default.
• W3023002011 creator A5020983805 @default.
• W3023002011 creator A5030112233 @default.
• W3023002011 creator A5045867300 @default.
• W3023002011 creator A5067982457 @default.
• W3023002011 creator A5070015133 @default.
• W3023002011 date "2020-05-07" @default.
• W3023002011 modified "2023-09-27" @default.
• W3023002011 title "Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis" @default.
• W3023002011 cites W1573851418 @default.
• W3023002011 cites W1963566476 @default.
• W3023002011 cites W1987748041 @default.
• W3023002011 cites W1998040228 @default.
• W3023002011 cites W2017183964 @default.
• W3023002011 cites W2024751773 @default.
• W3023002011 cites W2051469644 @default.
• W3023002011 cites W2059066086 @default.
• W3023002011 cites W2059796825 @default.
• W3023002011 cites W2086812115 @default.
• W3023002011 cites W2130355701 @default.
• W3023002011 cites W2137708344 @default.
• W3023002011 cites W2326911230 @default.
• W3023002011 cites W2606085194 @default.
• W3023002011 cites W2777074421 @default.
• W3023002011 cites W2792715803 @default.
• W3023002011 cites W2987455476 @default.
• W3023002011 cites W4240271001 @default.
• W3023002011 doi "https://doi.org/10.1001/jamanetworkopen.2020.4339" @default.
• W3023002011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7206503" @default.
• W3023002011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32379333" @default.
• W3023002011 hasPublicationYear "2020" @default.
• W3023002011 type Work @default.
• W3023002011 sameAs 3023002011 @default.
• W3023002011 citedByCount "8" @default.
• W3023002011 countsByYear W30230020112021 @default.
• W3023002011 countsByYear W30230020112022 @default.
• W3023002011 countsByYear W30230020112023 @default.
• W3023002011 crossrefType "journal-article" @default.
• W3023002011 hasAuthorship W3023002011A5007895609 @default.
• W3023002011 hasAuthorship W3023002011A5009520384 @default.
• W3023002011 hasAuthorship W3023002011A5014104761 @default.
• W3023002011 hasAuthorship W3023002011A5020983805 @default.
• W3023002011 hasAuthorship W3023002011A5030112233 @default.
• W3023002011 hasAuthorship W3023002011A5045867300 @default.
• W3023002011 hasAuthorship W3023002011A5067982457 @default.
• W3023002011 hasAuthorship W3023002011A5070015133 @default.
• W3023002011 hasBestOaLocation W30230020111 @default.
• W3023002011 hasConcept C118487528 @default.
• W3023002011 hasConcept C118552586 @default.
• W3023002011 hasConcept C119060515 @default.
• W3023002011 hasConcept C126322002 @default.
• W3023002011 hasConcept C142724271 @default.
• W3023002011 hasConcept C168563851 @default.
• W3023002011 hasConcept C187212893 @default.
• W3023002011 hasConcept C204787440 @default.
• W3023002011 hasConcept C27081682 @default.
• W3023002011 hasConcept C2776572573 @default.
• W3023002011 hasConcept C2778257484 @default.
• W3023002011 hasConcept C2780640218 @default.
• W3023002011 hasConcept C71924100 @default.
• W3023002011 hasConceptScore W3023002011C118487528 @default.
• W3023002011 hasConceptScore W3023002011C118552586 @default.
• W3023002011 hasConceptScore W3023002011C119060515 @default.
• W3023002011 hasConceptScore W3023002011C126322002 @default.
• W3023002011 hasConceptScore W3023002011C142724271 @default.
• W3023002011 hasConceptScore W3023002011C168563851 @default.
• W3023002011 hasConceptScore W3023002011C187212893 @default.
• W3023002011 hasConceptScore W3023002011C204787440 @default.
• W3023002011 hasConceptScore W3023002011C27081682 @default.
• W3023002011 hasConceptScore W3023002011C2776572573 @default.
• W3023002011 hasConceptScore W3023002011C2778257484 @default.
• W3023002011 hasConceptScore W3023002011C2780640218 @default.
• W3023002011 hasConceptScore W3023002011C71924100 @default.
• W3023002011 hasIssue "5" @default.
• W3023002011 hasLocation W30230020111 @default.
• W3023002011 hasLocation W30230020112 @default.
• W3023002011 hasLocation W30230020113 @default.
• W3023002011 hasLocation W30230020114 @default.
• W3023002011 hasOpenAccess W3023002011 @default.
• W3023002011 hasPrimaryLocation W30230020111 @default.
• W3023002011 hasRelatedWork W1940014806 @default.
• W3023002011 hasRelatedWork W2002125344 @default.
• W3023002011 hasRelatedWork W2042767492 @default.
• W3023002011 hasRelatedWork W2134402139 @default.
• W3023002011 hasRelatedWork W2289159721 @default.
• W3023002011 hasRelatedWork W2415280530 @default.
• W3023002011 hasRelatedWork W2617222556 @default.
• W3023002011 hasRelatedWork W3109248600 @default.
• W3023002011 hasRelatedWork W4385798292 @default.
• W3023002011 hasRelatedWork W2094746137 @default.
• W3023002011 hasVolume "3" @default.
• W3023002011 isParatext "false" @default.
• W3023002011 isRetracted "false" @default.
• W3023002011 magId "3023002011" @default.

• next